Effects of captopril on cardiorenal hemodynamics in patients with severe chronic congestive heart failure
Related Experiment Videos
Insights
Captopril improved heart function and reduced vascular resistance in heart failure patients. Its beneficial effects on renal blood flow are primarily due to inhibiting the renin-angiotensin system.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Chronic congestive heart failure (CHF) presents significant challenges in managing cardiorenal function.
- The renin-angiotensin system (RAS) plays a crucial role in cardiovascular and renal homeostasis.
Purpose of the Study:
- To investigate the effects of captopril on cardiorenal function in patients with CHF.
- To elucidate the mechanisms underlying captopril's effects, particularly its impact on the RAS.
Main Methods:
- A single oral dose of captopril was administered to 16 CHF patients.
- Cardiac indices, total systemic vascular resistance, plasma renin activity (PRA), and plasma aldosterone were measured.
- Renal plasma flow and renal blood flow were monitored during 7-day captopril therapy in 10 patients.
- Aprotinin infusion was used in some subjects to assess the role of the kallikrein-kinin system.
Main Results:
- Captopril significantly increased cardiac indices and decreased total systemic vascular resistance.
- These hemodynamic improvements were more pronounced in patients with higher baseline PRA.
- Renal plasma flow and renal blood flow increased during captopril therapy, especially in those with higher PRA.
- Aprotinin did not alter captopril's effect on renal plasma flow, suggesting limited involvement of the kallikrein-kinin system.
Conclusions:
- Captopril effectively reduces systemic vascular resistance in CHF patients by inhibiting the renin-angiotensin system.
- The observed renal vasodilation induced by captopril appears to be a direct consequence of RAS inhibition.
- The kallikrein-kinin system and kinin-mediated prostaglandins do not seem to play a significant role in captopril's renal effects.
Abstract:
The effects of captopril on cardiorenal function were studied in patients with chronic congestive heart failure. A single oral dose of captopril in 16 patients significantly increased cardiac indices and decreased total systemic vascular resistance. These changes were greater in subjects with higher baseline plasma renin activity (PRA). The increase in PRA and decrease in plasma aldosterone were also greater in this group. During 7 days of captopril therapy, renal plasma flow distinctly increased in 10 patients in whom renal function was followed. The increase in renal blood flow was greater in subjects with higher PRA. Simultaneous infusion of aprotinin in eight of these subjects did not affect the captopril-induced increase in renal plasma flow: these responses were the same in both PRA subgroups. The results suggest that captopril reduces total systemic vascular resistance in patients with chronic congestive heart failure through the inhibition of the renin-angiotensin system and the preferential renal vasodilating effect of captopril seems exclusively to be the sole result of this inhibition, with the kallikrein-kinin system or kinin-mediated prostaglandins not playing a major role.